NCT03755791 2025-12-11
COSMIC-312
Exelixis
Phase 3 Active not recruiting
Clinical Trials
10 trialsNCT00606866 2023-11-29
MRI
University of Chicago
Phase 3 Completed
NCT02323906 2017-03-20
Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer
Celgene
Phase 1 Terminated
NCT00576056 2017-02-15
Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC
University of Pittsburgh
Phase 2 Terminated
NCT00941863 2016-03-22
Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)
Bayer
Phase 1 Completed
NCT01009593 2012-09-10
Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
Abbott
Phase 3 Terminated
NCT00771147 2012-06-15
PONDIAC
Bayer
Completed
NCT01556815 2012-04-25
Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma
Shandong Cancer Hospital and Institute
Phase 2 Unknown
NCT01214343 2011-06-15
Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC
Ministry of Health, Labour and Welfare, Japan
Phase 3 Unknown
NCT00895674 2010-09-30
Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar
Bayer
Completed